Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Rewind 15 seconds
Fast Forward 15 seconds
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

More episodes from "Pharmaceutical Executive"